How to access Tegsedi from the UAE — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A UAE patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Tegsedi (inotersen) from their treating neurologist, often in coordination with a multidisciplinary amyloid clinic in Abu Dhabi, Dubai, or Sharjah. Tegsedi is FDA-approved for this indication and is an antisense oligonucleotide (ASO) developed by Ionis / Akcea (now Sobi). It is not routinely stocked through UAE hospital pharmacies for this indication, which is why access typically runs through the named-patient import pathway.

This guide explains the legal pathway, the documentation your neurologist prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Tegsedi is a subcutaneous antisense oligonucleotide that suppresses hepatic TTR production. It is self-administered (or caregiver-administered) weekly by subcutaneous injection after in-clinic training. The class's monitoring profile is the distinguishing clinical feature: Tegsedi carries a REMS programme for thrombocytopenia and glomerulonephritis, which translates into mandatory weekly platelet counts and routine urine protein / serum creatinine monitoring throughout therapy. Your neurologist will establish baseline neuropathy impairment scoring (NIS+7), polyneuropathy disability score, platelet count, renal function, and vitamin A level (Tegsedi requires vitamin A supplementation). Weekly monitoring discipline is the single most important operational commitment patients and families make on Tegsedi.

Is Tegsedi legally importable into the UAE?

Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority operated by the Department of Health (DoH) in Abu Dhabi and the Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.

The named-patient mechanism permits a UAE-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally available alternative suits the specific patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented end-to-end. hATTR polyneuropathy has limited disease-specific options on UAE formularies.

How the pathway works, step by step

1. Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and a clinical rationale letter.
2. Baseline assessment. NIS+7, polyneuropathy disability score, platelet count, renal function (eGFR, urine protein/creatinine), liver panel, vitamin A level.
3. MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, monitoring plan (mandatory weekly platelets / routine renal panel), patient reference, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Tegsedi from authorised distribution under DSCSA.
5. Cold-chain shipment. Tegsedi requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
6. Arrival, dispensing, and self-administration training. The hospital pharmacy releases product; the neurology clinic provides self-injection training and sets up the weekly monitoring schedule.

What documentation your physician needs

• Clinical rationale letter confirming hATTR polyneuropathy and Tegsedi as the indicated therapy
• Verification of UAE medical license
• TTR genetic test result
• Baseline NIS+7 and polyneuropathy disability score
• Baseline platelet count, renal function, liver panel, vitamin A level
• Weekly platelet / routine renal monitoring plan
• Planned dosing schedule (weekly SC) and vitamin A supplementation plan

Reserve Meds provides a physician documentation kit bundling the templates MoHAP reviewers expect for rare-disease neurology named-patient imports with mandated monitoring.

Costs and timing

Tegsedi for hATTR polyneuropathy is a substantial rare-disease therapy. Reference US cash-pay for a full annual course (weekly subcutaneous dosing) typically sits in the mid-to-high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, cold-chain logistics, MoHAP documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete MoHAP application is submitted. Weekly refill cadence is established with the hospital pharmacy thereafter.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and MoHAP review, including the monitoring-plan documentation reviewers expect.
• Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
• Concierge case lead. A named point of contact coordinating weekly supply and monthly refill logistics.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. The mandatory weekly platelet / renal monitoring is the responsibility of your neurologist and the dispensing hospital pharmacy; we support logistics, not clinical oversight. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.

How is Tegsedi different from Wainua? Both are subcutaneous antisense oligonucleotides that silence hepatic TTR, but they differ meaningfully in day-to-day burden. Tegsedi is weekly with mandatory weekly platelet counts and routine renal monitoring. Wainua is monthly with a cleaner monitoring profile (no REMS-level platelet programme). Your neurologist will select based on clinical picture, patient preference, and monitoring logistics.

What if my platelets drop? The monitoring protocol exists specifically to catch this early. Your neurologist manages dose adjustments or therapy changes; we support logistics if the plan changes.

Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Tegsedi coordination in the UAE.

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.